MedTrace Logo

Retrospective-prospective Study to Evaluate Treatment Management and Outcomes of Patients With Waldenström's Macroglobulinemia (WM) Treated in Italy According to the Zanubrutinib (Brukinsa®) Compassionate Use Program (CUP) and in Common Practice Following Commercial Approval.

NCT06441214 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 212

Last updated 2026-01-05

No results posted yet for this study

Summary

This is a non-interventional, observational, retrospective and prospective multicenter Italian study, to describe treatment management and outcomes of Waldenström's Macroglobulinemia (WM) patients treated according to the Italian Compassionate Use Program (CUP) and receiving zanubrutinib following its commercial approval.

Conditions

  • Waldenström's Macroglobulinemia (WM)

Interventions

DRUG

Zanubrutinib

Patients will be treated with Zanubrutinib as per routine clinical practice.

Sponsors & Collaborators

  • Fondazione Italiana Linfomi - ETS

    lead OTHER

Principal Investigators

  • Anna Maria Frustaci · ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-13
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06441214 on ClinicalTrials.gov